{"ticker": {"uuid": "6cfb9a18-9b05-4bc8-a278-6619593abc82", "symbol": "EDIT", "name": "Editas Medicine Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Editas Medicine stock holds the line as pipeline work continues.", "summary": "Editas Medicine remains focused on its gene-editing pipeline and Nasdaq listing, emphasizing clinical progress and regulatory milestones. As a clinical-stage company, its value is tied to development updates and balance-sheet durability, rather than immediate sales. Investors mon", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/editas-medicine-stock-holds-the-line-as-pipeline-work-continues/69682816", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:13:12", "published_display": "03 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS:EDIT) has been added to the Russell Small Cap Comp Growth Benchmark. The company, a genome-editing firm, is engaged in developing genomic medicines using CRISPR technology to treat various serious diseases. This inclusion highlights its growing rec", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd80ff25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:41", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2500 Growth Benchmark. This news follows a series of recent announcements, including the company's inclusion in several other Russell benchmarks and updates on its preclinical data for EDIT-401 for hyperlipidemi", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-2500-growth-benchmark-ce7f5fdfda80f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:41", "published_display": "29 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell Microcap Growth Benchmark Index as of June 28, 2026. This inclusion is among several other Russell index additions for the company, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000 ", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:10:36", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2000 Growth Benchmark, a significant inclusion for the genome-editing company. This news, published on June 29, 2026, also notes its addition to the Russell Small Cap Comp Growth Benchmark and Russell 2500 Growt", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:41", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article provides financial information for Editas Medicine, Inc. (NASDAQ: EDIT), specifically focusing on its forward price-to-sales ratio. It details where the data is sourced from, including ICE Data Services and FactSet, and notes that the information is provided by Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:56", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article displays the forward Enterprise Value to EBITDA for Editas Medicine, Inc. (NASDAQ: EDIT). It presents basic financial and market information related to the company, indicating that the market was closed at the time of the data display. The page is sourced from Tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:42:45", "published_display": "27 Jun 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Editas Medicine, Inc. \u2013 LSE:0IFK", "summary": "This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing the company's identifier on the London Stock Exchang", "url": "https://www.tradingview.com/symbols/LSE-0IFK/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:45", "published_display": "27 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article displays the \"Price to book forward\" financial metric for Editas Medicine, Inc. (NASDAQ: EDIT). It presents a value for a specific period and notes any changes in that value, but does not provide additional details or analysis. The content appears to be a stub or a d", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:52", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Editas Medicine, Inc. \u2013 LSE:0IFK", "summary": "This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It appears to be a financial data page from TradingView, displaying market status and a link to detailed financial", "url": "https://www.tradingview.com/symbols/LSE-0IFK/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:52", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT)", "summary": "This article provides an overview of Editas Medicine, Inc. (NASDAQ: EDIT) financial actuals and estimates, stock performance, and analyst forecasts. It details historical stock prices, market capitalization, volatility, and upcoming earnings reports, along with other financial st", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:52", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (FWB:8EM)", "summary": "This article provides an overview of Editas Medicine, Inc.'s financial data and analyst estimates, including income statement, balance sheet, and cash flow. It also covers analyst price forecasts, historical stock prices, upcoming earnings dates, and quarterly financial results s", "url": "https://www.tradingview.com/symbols/FWB-8EM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:42:45", "published_display": "26 Jun 2026 21:42", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK)", "summary": "This article provides an overview of Editas Medicine, Inc. (LSE:0IFK) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analysts' price targets, and key financial metrics like earnings, revenue,", "url": "https://www.tradingview.com/symbols/LSE-0IFK/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T18:09:25", "published_display": "26 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDIT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Editas Medicine, Inc. (EDIT) stock, including analyst price targets, past performance, and key financial metrics. It highlights the stock's current price, market capitalization, and upcoming earnings report, while also addressing frequently as", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:25", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew", "summary": "This document is a Form 4 filing for Editas Medicine, detailing changes in beneficial ownership of securities for Director Andrew Hirsch. Such filings are made with the SEC to report transactions by company insiders.", "url": "https://www.moomoo.com/news/notice/307569748/editas-medicine-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-24T08:40:00", "published_display": "24 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica", "summary": "This article provides a Form 4 statement for Editas Medicine, detailing changes in beneficial ownership of securities for Director Jessica Hopfield. The document reports on transactions that have altered her holdings in the company.", "url": "https://www.moomoo.com/news/notice/307569761/editas-medicine-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-23T20:11:06", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike", "summary": "Editas Medicine, Inc. director David Scadden was granted 51,700 stock options with an exercise price of $2.55 per share, set to expire on June 16, 2036. The options were granted on June 17, 2026, and will vest in full on June 17, 2027. This transaction is a compensation-related a", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-b76e2c422c2c.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:11:06", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55", "summary": "Editas Medicine director Jessica Hopfield was granted 51,700 stock options at an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. This transaction was reported in a Form 4 filing an", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-dfdc0415188b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T09:10:52", "published_display": "23 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options", "summary": "Editas Medicine director Andrew Hirsch was granted 51,700 stock options with an exercise price of $2.55 per share. These options, granted on June 17, 2026, are scheduled to fully vest on June 17, 2027, and expire on June 16, 2036. This grant serves as a compensation award, and no", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-0f8a532b6c0a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:45", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Editas Medicine, Inc. Insider Trading Activity", "summary": "Editas Medicine, Inc. director Bernadette Connaughton received a grant of 51,700 stock options with an exercise price of $2.55 per share, vesting fully on June 17, 2027, and expiring on June 16, 2036. This transaction is considered neutral in sentiment and filing impact, with no ", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-bfc7123420c8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Editas Medicine For: 22 June By Investing.com", "summary": "This article from Investing.com is a straightforward financial market update, primarily serving as a placeholder for a \"Form 4\" filing for Editas Medicine (EDIT) dated June 22. It briefly mentions the stock's performance on that day, showing a 4.09% increase. The content also inc", "url": "https://ca.investing.com/news/stock-market-news/form-4-editas-medicine-for-22-june-93CH-4701809", "source_name": "Investing.com Canada", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike", "summary": "Editas Medicine director Elliott M. Levy was granted 51,700 stock options with an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. Following this grant, Levy holds 51,700 derivative", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-cd189e996523.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine elects two directors and ratifies auditor at annual meeting", "summary": "Editas Medicine (NASDAQ:EDIT) held its 2026 Annual Meeting where shareholders elected Bernadette Connaughton and Elliott Levy as Class I directors and approved executive compensation on an advisory basis. Shareholders also ratified PricewaterhouseCoopers LLP as the independent re", "url": "https://m.uk.investing.com/news/sec-filings/editas-medicine-elects-two-directors-and-ratifies-auditor-at-annual-meeting-93CH-4736602?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-19T13:11:47", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting", "summary": "Editas Medicine (EDIT) held its 2026 annual stockholder meeting where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company's n", "url": "https://www.stocktitan.net/sec-filings/EDIT/8-k-editas-medicine-inc-reports-material-event-f6313bcf7448.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:17:01", "published_display": "18 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Editas Medicine Inc's (EDIT) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also displays current stock information such as", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edit/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:30", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Editas Medicine Inc (EDIT), including business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant financial data, resulting in no information being avail", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edit/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:30", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medicine Inc", "summary": "COMMODORE CAPITAL LP has acquired a significant 9.90% stake in Editas Medicine Inc, purchasing 16,045,802 shares at $3.08 each. This strategic investment, valued at $1.73 billion, integrates Editas Medicine, a clinical-stage biotechnology company focused on CRISPR technology, int", "url": "https://www.gurufocus.com/news/8903966/commodore-capital-lp-acquires-significant-stake-in-editas-medicine-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-06T04:39:38", "published_display": "06 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc", "summary": "RA CAPITAL MANAGEMENT, L.P. has acquired 8,889,000 shares of Editas Medicine Inc for $3.57 per share, making it a new holding and a 5.80% position in the biotechnology firm's portfolio. This strategic investment, impacting the firm's portfolio by 0.34%, highlights a continued int", "url": "https://www.gurufocus.com/news/8903990/ra-capital-management-lp-acquires-significant-stake-in-editas-medicine-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-06T04:39:38", "published_display": "06 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) CEO logs automatic, tax-related share sale", "summary": "Editas Medicine's CEO, O'Neill Gilmore Neil, reported an automatic sale of 15,380 shares of common stock at a weighted average price of $2.7011 per share on June 3, 2026. This transaction was not discretionary but was executed under a pre-established plan to cover tax withholding", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-77caf92c3351.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:56", "published_display": "05 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPQmh1VURGZVNEcmZmNE9ZTnBYX1RNQldKU2wwakJWTERlT3Z5Z1AtLUdlQVdZckxIekFnLVRnS1RvcjVWLTRhYmJ0Zlk0ZVBMV3R3VzRTRTZQRXkzdUhWN2xiTG5BSjlRaTNfY1l6dlJ0S3VEcUt3LXpIZmpFZmg0OGwxaUxMQUxuUGd6dkcyVjYydw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/29ff5d15-93b2-3482-aa76-4bb9107c705c/crispr-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-05-31T16:31:48+00:00", "published_display": "31 May 2026 16:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-announces-updated-presentation-200100011.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:01:00+00:00", "published_display": "28 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbmZYN1E2LXVXOFE5OGRMUU5FUWlsRnJKNjhsTkFxblpOSFA0ckV5MnVoZTNDTkc2TVZvdjdWYmxPWjl0ZEwtZTdiUEtzUndTS2d6aE5DRWp6aVlpeTY4cUJ4WGE4S0tTM3ZnU3hrYjNyUVc5dVJBMFZwTE93akhSakpVa1FqeU0zbVV1dXBNeGNEN3QtUk9WdEtuRWM4TG9fd0tMVHpqLXpia3Y5Y1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Prices Public Offering of Shares, Warrants", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/editas-medicine-prices-public-offering-144404192.html", "source_name": "MT Newswires", "published_at": "2026-05-26T14:44:04+00:00", "published_display": "26 May 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/editas-medicine-proposes-public-stock-103830964.html", "source_name": "MT Newswires", "published_at": "2026-05-26T10:38:30+00:00", "published_display": "26 May 2026 10:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-presents-edit-401-100100102.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T10:01:00+00:00", "published_display": "26 May 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMWFRUkxBRzlESV9xWVZmZkJRQTE1OWxwRk1kUEJ4YjFfMFVoNS1rVlpVbVJqblQ4NWIxVUh6V1lib0NWY2hjR0pTZTNxZWVjU2dhRDZzeGkxdWtvRjAxMEdfQXdjY0lsdWZaLXJnZEtSdkFabWkxNUtJdllVQWh5UWRlQmdRY1g5OW1lUmJidUFpZ3NDQ1llSjBVNTRIMmptQ2liLTgta0MwNmI4a0hYZW9INENWN1FreVlra0NpUnVaLTFmMm5qYnI5YjBlVHVSbHhteGZqWWpaTzBN?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMEJsb24yMkZoallqNkxtSm5yUUtrblQ3UzFPRGdNaENfN0pKQk5uXzBsdEFCMkZWczlEeS1RRzVER3dselo4M3VJb1FHaFc1dC1OMzFMR3B1cjlwNXRIT21yR3l1cEZsbkRWZFZ0M2FaT0ZLQkVGaXBWZlJ4RDRaTURib3IzN3NWWHlmdUt0bzlkbzJyQklDcFFzaGdOanVyX3dYVjBnLU1peW84MF84aUUxY0UxQVRMRU1DTDFGcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQ25LT1hXVmFqTzFtWmxNWWROT1F0TTJNaFN6QjZDSGkxaHR4ZFJiYk9Wb2xCcmpNSFBreV83cGU0NXRZX1o2bi1nQUlkTEhxbWZwSk9CZEQyaXprRDNPeVJBNGdjLXdMNXhLR1NCLXBLVUp1Vkh3bDhjSmdPeEI3TEloTXFGVVhHQnZSOTFCUnZCYXhZVnJ5ZG91Tm44dUwtcUdTb05nb0tMdG1i?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas offering links warrant window to cholesterol trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWFlPWFJOY1FqWWh3YkxlS3F4cVE3UGJrNWRxb1MzX25wV1k5cnJPZVVBeE5PUkVtUmlEdWNlSFlSd3VEMmZSTFVZVVlsLXVnRkJOcld0cDlSLVg0V0o2RVlKeFVtWW9sZDlJaUMzUUxyLWM0QVV5VzBmNmFTLVVzWHpmbk1XMGN2cjNUbmgxczhWblp4Y1duNl9CR0twdENnSHpLcHk4Y2dOY3Rqb2JfVkx3RW1EVFNQSlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine stock tumbles on stock offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxORDlCZjI1b0lNdHNrZnoxTTYyM3ZtUVMwQk5nY1FjQ1lFWjd6eGpRclFBQmhrT09JcWR4bHFRWGdpSXZMSnZiaXRxdVQ3anhJVWxZWnpZMU9hejFSb1BycnpaOXFaV29RNVViSWRsVWN1TXg5VWh6VE92WFJzMWtfMTR1ZjFVSW41am9nTENxeVJFRGhLREdUcWhvSFpTV29TSFgyMFlMMEgxbW5QS3YyWUExS2xVQzRQQ0NZNEx2bw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine launches public offering of stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORlc5WDJMMU1GdlBJcGhDcmY5TG9IYXZaWUJldm1uU1FfQ3I0NVFYbXp0TmJTd3BUQWZyRDhkSUlSZ2otTVhhYVVkYjd4UFJUQ0RNdlVHRERrcHE0VTFBR0F4UnUyRDFoUFYweGM3SFpxcElzTF9CMFFobDVpdjFzbjVIbEZ0VElobHNGa0h5ajVaMzA3dXF6LWhsZGY2U1BmQ24xUjFyblJiUU1RTEZReEs3bHE1bGZsUEU4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene-editing firm Editas moves to sell new shares and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQktpT2g3dkV1clJEaGczZFcxemtsOXd0Zm56ZnBqdDZjUk83Q1ZOcDRUOUlOMGo4Rk9kdEwtcE1fNnpsSnFVVWNOWGhRWHFVdG9aOEdNSnlUTDR5MnFFRW9WX3F0QVl3S3FsR25UdEw3dlhJMWRad2ktR3ZxdTlMR0ZhaWtSZ2w5ZlVleVFRLTdFLV9KdVNvekZGV3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-lead-therapy-cuts-104055294.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:40:55+00:00", "published_display": "14 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine presents preclinical data on EDIT-401 therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb0tHZ2s1Z01PWkxNaHVITWxFUGd0ZDNOVTMwWlk4aUdpdXNnc0x5cld5NGVLbEpuNXE4d0J0QS0tQzhtakhJdkRtU3VfNDB6QjlieW1GRVh0c3pGbTJ3a2UwVF9VcXBoVEpwc2dQZVhIOW51VFhvNTZhQzVVUUl3cEp0VDB4ZGg1OWNjV0xiaGpjZTQzaGozUWsxVXVmR1pva0tfSlpJc1V1a3lEZkdPbDM4NVNVb081?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVS1lRlFMMGJmaXctbW9sbmpwdUwwY3lqRUVzZUVLYUJDaXNJcksySXNtWWY3R0dVQlhsQmFYb3J1bmxjWXBINjdHelBsbmtqV1dNdWtjMHB3ZVJlOVd3alRockVDSWJiNjEtNlZOa3U5ZTR1SmtDVnc0bklhdXZTdkg3QUhJWUlvUnhpOXNUYnNaZVRDcDV4aEJ3U014ams?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPamxXVjItMnlRWm41TWRxRUFxTk9pcnJDazNiYU1LUVdCYWpaZ2RsZ0t2cTlqYVE0am1Fc2lKNXdKZXFWUkFFdldEUWpLbm1Ga3dhNzUtNGoxOE9OckpXOFo4ZWZrcTNBcmhsV3d2cG1WT0VMR3N2bU1VMzdwMmRnTE5fek1VVU1kS2t2MGFwOA?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Editas Medicine Announces U.S. Patent and Trademark Office", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwJBVV95cUxPWUFOOGVOekNQVEd5bXlNMHpYQUpjOURMOVo2T3MtNXpUODZCRlgxa2t1alMwVWNDajgtTnpRYjNFQlRIVWJpZldiOWRPTTlkNzFUUjBGSVJPamZZZk5mVEZ0V0c0eWJTRmdyWWZ1V0FuVDAxV3hOVnhxMktIYTl3QmhMYUxCWVJqS3dCQUNESzlBVWtUellTN2JEbm9oMWtqYWdUQnc2dDJsanBmaEEwVTZwVkExLUQzbXVlSzljWG9iT2VubWU4cDUyS1VWMzlxLXlyc09wU2VrZS1tSHhLUEtGMEp3bmtseXhmRlVEd0hqdDBHZnJNV0R4OWxxQ2FGb21HOVYxNXg2RVV2c1plMEFsVlhvajU2eGxvT0Z1a0RaRUZhcl9VVk1sd3BmN2MtZmUtV3hlMEFlOEJKaENn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A key U.S. CRISPR patent fight swings again toward Editas partner Broad", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOcHltUW8weV82akpQdU41MWs2RjhZQmJqRG1uLW4ydmcxemg4OHRHWUNhc0VTa2pWVzVoUGtsY3lVTVA5NlFHakxYWWVHdWNCbW81WTA1OWZYOV9qLU9XcWlETEJPZ21tRVZ5SE10b2RJRTBZS2lxNE1PaG9BOFFVLUo4NTZlZWM1S1F1Z1ZqcFB5cmcwbjdlRWJZMlppWE1rVmFmeTdkR1VQUkdBWXRFS1hGSTFTMEI2dGtXaDlwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline Challenges - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNeWdrN0gzeE5CbWhhNUJZWVc4THZvbXF4UjZZWEdUaUg1aXdBOGZJSEVlcEE0Qy0tWFFDcDVyQlVLMFhpaE90eWJIMzVSOFBhS1FHUUVPbEdLUFl3VW9OQm9MSFpVSDhDbGVkSk1SU05Eak40ZmNfQXBhckJQY0Iyd2RNS3BtaVFDZmpKMUJtT0xQb3dBVmNMMHhBUzRFQlkyWXlScEMzNXFYbFYwS254emlxVDhiVDN1T2c?oc=5", "source_name": "IndexBox", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Editas Medicine stock holds the line as pipeline work continues.", "summary": "Editas Medicine remains focused on its gene-editing pipeline and Nasdaq listing, emphasizing clinical progress and regulatory milestones. As a clinical-stage company, its value is tied to development updates and balance-sheet durability, rather than immediate sales. Investors mon", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/editas-medicine-stock-holds-the-line-as-pipeline-work-continues/69682816", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T19:13:12", "published_display": "03 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS:EDIT) added to Russell Small Cap Comp Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS:EDIT) has been added to the Russell Small Cap Comp Growth Benchmark. The company, a genome-editing firm, is engaged in developing genomic medicines using CRISPR technology to treat various serious diseases. This inclusion highlights its growing rec", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdd80ff25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:40:41", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2500 Growth Benchmark. This news follows a series of recent announcements, including the company's inclusion in several other Russell benchmarks and updates on its preclinical data for EDIT-401 for hyperlipidemi", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-2500-growth-benchmark-ce7f5fdfda80f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:40:41", "published_display": "29 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell Microcap Growth Benchmark Index", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell Microcap Growth Benchmark Index as of June 28, 2026. This inclusion is among several other Russell index additions for the company, including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000 ", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:10:36", "published_display": "29 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2000 Growth Benchmark", "summary": "Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2000 Growth Benchmark, a significant inclusion for the genome-editing company. This news, published on June 29, 2026, also notes its addition to the Russell Small Cap Comp Growth Benchmark and Russell 2500 Growt", "url": "https://www.marketscreener.com/news/editas-medicine-inc-nasdaqgs-edit-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:41", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article provides financial information for Editas Medicine, Inc. (NASDAQ: EDIT), specifically focusing on its forward price-to-sales ratio. It details where the data is sourced from, including ICE Data Services and FactSet, and notes that the information is provided by Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:56", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article displays the forward Enterprise Value to EBITDA for Editas Medicine, Inc. (NASDAQ: EDIT). It presents basic financial and market information related to the company, indicating that the market was closed at the time of the data display. The page is sourced from Tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:42:45", "published_display": "27 Jun 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Editas Medicine, Inc. \u2013 LSE:0IFK", "summary": "This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing the company's identifier on the London Stock Exchang", "url": "https://www.tradingview.com/symbols/LSE-0IFK/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:45", "published_display": "27 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Editas Medicine, Inc. \u2013 NASDAQ:EDIT", "summary": "This article displays the \"Price to book forward\" financial metric for Editas Medicine, Inc. (NASDAQ: EDIT). It presents a value for a specific period and notes any changes in that value, but does not provide additional details or analysis. The content appears to be a stub or a d", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:52", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Editas Medicine, Inc. \u2013 LSE:0IFK", "summary": "This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It appears to be a financial data page from TradingView, displaying market status and a link to detailed financial", "url": "https://www.tradingview.com/symbols/LSE-0IFK/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:52", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT)", "summary": "This article provides an overview of Editas Medicine, Inc. (NASDAQ: EDIT) financial actuals and estimates, stock performance, and analyst forecasts. It details historical stock prices, market capitalization, volatility, and upcoming earnings reports, along with other financial st", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:52", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (FWB:8EM)", "summary": "This article provides an overview of Editas Medicine, Inc.'s financial data and analyst estimates, including income statement, balance sheet, and cash flow. It also covers analyst price forecasts, historical stock prices, upcoming earnings dates, and quarterly financial results s", "url": "https://www.tradingview.com/symbols/FWB-8EM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:42:45", "published_display": "26 Jun 2026 21:42", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK)", "summary": "This article provides an overview of Editas Medicine, Inc. (LSE:0IFK) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analysts' price targets, and key financial metrics like earnings, revenue,", "url": "https://www.tradingview.com/symbols/LSE-0IFK/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T18:09:25", "published_display": "26 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDIT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Editas Medicine, Inc. (EDIT) stock, including analyst price targets, past performance, and key financial metrics. It highlights the stock's current price, market capitalization, and upcoming earnings report, while also addressing frequently as", "url": "https://www.tradingview.com/symbols/NASDAQ-EDIT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:25", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew", "summary": "This document is a Form 4 filing for Editas Medicine, detailing changes in beneficial ownership of securities for Director Andrew Hirsch. Such filings are made with the SEC to report transactions by company insiders.", "url": "https://www.moomoo.com/news/notice/307569748/editas-medicine-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-24T08:40:00", "published_display": "24 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica", "summary": "This article provides a Form 4 statement for Editas Medicine, detailing changes in beneficial ownership of securities for Director Jessica Hopfield. The document reports on transactions that have altered her holdings in the company.", "url": "https://www.moomoo.com/news/notice/307569761/editas-medicine-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-23T20:11:06", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike", "summary": "Editas Medicine, Inc. director David Scadden was granted 51,700 stock options with an exercise price of $2.55 per share, set to expire on June 16, 2036. The options were granted on June 17, 2026, and will vest in full on June 17, 2027. This transaction is a compensation-related a", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-b76e2c422c2c.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:11:06", "published_display": "23 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55", "summary": "Editas Medicine director Jessica Hopfield was granted 51,700 stock options at an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. This transaction was reported in a Form 4 filing an", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-dfdc0415188b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T09:10:52", "published_display": "23 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options", "summary": "Editas Medicine director Andrew Hirsch was granted 51,700 stock options with an exercise price of $2.55 per share. These options, granted on June 17, 2026, are scheduled to fully vest on June 17, 2027, and expire on June 16, 2036. This grant serves as a compensation award, and no", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-0f8a532b6c0a.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:45", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Editas Medicine, Inc. Insider Trading Activity", "summary": "Editas Medicine, Inc. director Bernadette Connaughton received a grant of 51,700 stock options with an exercise price of $2.55 per share, vesting fully on June 17, 2027, and expiring on June 16, 2036. This transaction is considered neutral in sentiment and filing impact, with no ", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-bfc7123420c8.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Editas Medicine For: 22 June By Investing.com", "summary": "This article from Investing.com is a straightforward financial market update, primarily serving as a placeholder for a \"Form 4\" filing for Editas Medicine (EDIT) dated June 22. It briefly mentions the stock's performance on that day, showing a 4.09% increase. The content also inc", "url": "https://ca.investing.com/news/stock-market-news/form-4-editas-medicine-for-22-june-93CH-4701809", "source_name": "Investing.com Canada", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike", "summary": "Editas Medicine director Elliott M. Levy was granted 51,700 stock options with an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. Following this grant, Levy holds 51,700 derivative", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-cd189e996523.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:40:17", "published_display": "22 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine elects two directors and ratifies auditor at annual meeting", "summary": "Editas Medicine (NASDAQ:EDIT) held its 2026 Annual Meeting where shareholders elected Bernadette Connaughton and Elliott Levy as Class I directors and approved executive compensation on an advisory basis. Shareholders also ratified PricewaterhouseCoopers LLP as the independent re", "url": "https://m.uk.investing.com/news/sec-filings/editas-medicine-elects-two-directors-and-ratifies-auditor-at-annual-meeting-93CH-4736602?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-19T13:11:47", "published_display": "19 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting", "summary": "Editas Medicine (EDIT) held its 2026 annual stockholder meeting where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company's n", "url": "https://www.stocktitan.net/sec-filings/EDIT/8-k-editas-medicine-inc-reports-material-event-f6313bcf7448.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:17:01", "published_display": "18 Jun 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Editas Medicine Inc's (EDIT) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also displays current stock information such as", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edit/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:30", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Editas Medicine Inc (EDIT), including business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant financial data, resulting in no information being avail", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edit/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:30", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medicine Inc", "summary": "COMMODORE CAPITAL LP has acquired a significant 9.90% stake in Editas Medicine Inc, purchasing 16,045,802 shares at $3.08 each. This strategic investment, valued at $1.73 billion, integrates Editas Medicine, a clinical-stage biotechnology company focused on CRISPR technology, int", "url": "https://www.gurufocus.com/news/8903966/commodore-capital-lp-acquires-significant-stake-in-editas-medicine-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-06T04:39:38", "published_display": "06 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc", "summary": "RA CAPITAL MANAGEMENT, L.P. has acquired 8,889,000 shares of Editas Medicine Inc for $3.57 per share, making it a new holding and a 5.80% position in the biotechnology firm's portfolio. This strategic investment, impacting the firm's portfolio by 0.34%, highlights a continued int", "url": "https://www.gurufocus.com/news/8903990/ra-capital-management-lp-acquires-significant-stake-in-editas-medicine-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-06T04:39:38", "published_display": "06 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) CEO logs automatic, tax-related share sale", "summary": "Editas Medicine's CEO, O'Neill Gilmore Neil, reported an automatic sale of 15,380 shares of common stock at a weighted average price of $2.7011 per share on June 3, 2026. This transaction was not discretionary but was executed under a pre-established plan to cover tax withholding", "url": "https://www.stocktitan.net/sec-filings/EDIT/form-4-editas-medicine-inc-insider-trading-activity-77caf92c3351.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:56", "published_display": "05 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPQmh1VURGZVNEcmZmNE9ZTnBYX1RNQldKU2wwakJWTERlT3Z5Z1AtLUdlQVdZckxIekFnLVRnS1RvcjVWLTRhYmJ0Zlk0ZVBMV3R3VzRTRTZQRXkzdUhWN2xiTG5BSjlRaTNfY1l6dlJ0S3VEcUt3LXpIZmpFZmg0OGwxaUxMQUxuUGd6dkcyVjYydw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/29ff5d15-93b2-3482-aa76-4bb9107c705c/crispr-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-05-31T16:31:48+00:00", "published_display": "31 May 2026 16:31", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-announces-updated-presentation-200100011.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T20:01:00+00:00", "published_display": "28 May 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbmZYN1E2LXVXOFE5OGRMUU5FUWlsRnJKNjhsTkFxblpOSFA0ckV5MnVoZTNDTkc2TVZvdjdWYmxPWjl0ZEwtZTdiUEtzUndTS2d6aE5DRWp6aVlpeTY4cUJ4WGE4S0tTM3ZnU3hrYjNyUVc5dVJBMFZwTE93akhSakpVa1FqeU0zbVV1dXBNeGNEN3QtUk9WdEtuRWM4TG9fd0tMVHpqLXpia3Y5Y1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Prices Public Offering of Shares, Warrants", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/editas-medicine-prices-public-offering-144404192.html", "source_name": "MT Newswires", "published_at": "2026-05-26T14:44:04+00:00", "published_display": "26 May 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/editas-medicine-proposes-public-stock-103830964.html", "source_name": "MT Newswires", "published_at": "2026-05-26T10:38:30+00:00", "published_display": "26 May 2026 10:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-presents-edit-401-100100102.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T10:01:00+00:00", "published_display": "26 May 2026 10:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMWFRUkxBRzlESV9xWVZmZkJRQTE1OWxwRk1kUEJ4YjFfMFVoNS1rVlpVbVJqblQ4NWIxVUh6V1lib0NWY2hjR0pTZTNxZWVjU2dhRDZzeGkxdWtvRjAxMEdfQXdjY0lsdWZaLXJnZEtSdkFabWkxNUtJdllVQWh5UWRlQmdRY1g5OW1lUmJidUFpZ3NDQ1llSjBVNTRIMmptQ2liLTgta0MwNmI4a0hYZW9INENWN1FreVlra0NpUnVaLTFmMm5qYnI5YjBlVHVSbHhteGZqWWpaTzBN?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces Proposed Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMEJsb24yMkZoallqNkxtSm5yUUtrblQ3UzFPRGdNaENfN0pKQk5uXzBsdEFCMkZWczlEeS1RRzVER3dselo4M3VJb1FHaFc1dC1OMzFMR3B1cjlwNXRIT21yR3l1cEZsbkRWZFZ0M2FaT0ZLQkVGaXBWZlJ4RDRaTURib3IzN3NWWHlmdUt0bzlkbzJyQklDcFFzaGdOanVyX3dYVjBnLU1peW84MF84aUUxY0UxQVRMRU1DTDFGcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQ25LT1hXVmFqTzFtWmxNWWROT1F0TTJNaFN6QjZDSGkxaHR4ZFJiYk9Wb2xCcmpNSFBreV83cGU0NXRZX1o2bi1nQUlkTEhxbWZwSk9CZEQyaXprRDNPeVJBNGdjLXdMNXhLR1NCLXBLVUp1Vkh3bDhjSmdPeEI3TEloTXFGVVhHQnZSOTFCUnZCYXhZVnJ5ZG91Tm44dUwtcUdTb05nb0tMdG1i?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas offering links warrant window to cholesterol trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPWFlPWFJOY1FqWWh3YkxlS3F4cVE3UGJrNWRxb1MzX25wV1k5cnJPZVVBeE5PUkVtUmlEdWNlSFlSd3VEMmZSTFVZVVlsLXVnRkJOcld0cDlSLVg0V0o2RVlKeFVtWW9sZDlJaUMzUUxyLWM0QVV5VzBmNmFTLVVzWHpmbk1XMGN2cjNUbmgxczhWblp4Y1duNl9CR0twdENnSHpLcHk4Y2dOY3Rqb2JfVkx3RW1EVFNQSlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine stock tumbles on stock offering announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxORDlCZjI1b0lNdHNrZnoxTTYyM3ZtUVMwQk5nY1FjQ1lFWjd6eGpRclFBQmhrT09JcWR4bHFRWGdpSXZMSnZiaXRxdVQ3anhJVWxZWnpZMU9hejFSb1BycnpaOXFaV29RNVViSWRsVWN1TXg5VWh6VE92WFJzMWtfMTR1ZjFVSW41am9nTENxeVJFRGhLREdUcWhvSFpTV29TSFgyMFlMMEgxbW5QS3YyWUExS2xVQzRQQ0NZNEx2bw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine launches public offering of stock and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORlc5WDJMMU1GdlBJcGhDcmY5TG9IYXZaWUJldm1uU1FfQ3I0NVFYbXp0TmJTd3BUQWZyRDhkSUlSZ2otTVhhYVVkYjd4UFJUQ0RNdlVHRERrcHE0VTFBR0F4UnUyRDFoUFYweGM3SFpxcElzTF9CMFFobDVpdjFzbjVIbEZ0VElobHNGa0h5ajVaMzA3dXF6LWhsZGY2U1BmQ24xUjFyblJiUU1RTEZReEs3bHE1bGZsUEU4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gene-editing firm Editas moves to sell new shares and warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQktpT2g3dkV1clJEaGczZFcxemtsOXd0Zm56ZnBqdDZjUk83Q1ZOcDRUOUlOMGo4Rk9kdEwtcE1fNnpsSnFVVWNOWGhRWHFVdG9aOEdNSnlUTDR5MnFFRW9WX3F0QVl3S3FsR25UdEw3dlhJMWRad2ktR3ZxdTlMR0ZhaWtSZ2w5ZlVleVFRLTdFLV9KdVNvekZGV3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-lead-therapy-cuts-104055294.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:40:55+00:00", "published_display": "14 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine presents preclinical data on EDIT-401 therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb0tHZ2s1Z01PWkxNaHVITWxFUGd0ZDNOVTMwWlk4aUdpdXNnc0x5cld5NGVLbEpuNXE4d0J0QS0tQzhtakhJdkRtU3VfNDB6QjlieW1GRVh0c3pGbTJ3a2UwVF9VcXBoVEpwc2dQZVhIOW51VFhvNTZhQzVVUUl3cEp0VDB4ZGg1OWNjV0xiaGpjZTQzaGozUWsxVXVmR1pva0tfSlpJc1V1a3lEZkdPbDM4NVNVb081?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVS1lRlFMMGJmaXctbW9sbmpwdUwwY3lqRUVzZUVLYUJDaXNJcksySXNtWWY3R0dVQlhsQmFYb3J1bmxjWXBINjdHelBsbmtqV1dNdWtjMHB3ZVJlOVd3alRockVDSWJiNjEtNlZOa3U5ZTR1SmtDVnc0bklhdXZTdkg3QUhJWUlvUnhpOXNUYnNaZVRDcDV4aEJ3U014ams?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPamxXVjItMnlRWm41TWRxRUFxTk9pcnJDazNiYU1LUVdCYWpaZ2RsZ0t2cTlqYVE0am1Fc2lKNXdKZXFWUkFFdldEUWpLbm1Ga3dhNzUtNGoxOE9OckpXOFo4ZWZrcTNBcmhsV3d2cG1WT0VMR3N2bU1VMzdwMmRnTE5fek1VVU1kS2t2MGFwOA?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine Announces U.S. Patent and Trademark Office", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwJBVV95cUxPWUFOOGVOekNQVEd5bXlNMHpYQUpjOURMOVo2T3MtNXpUODZCRlgxa2t1alMwVWNDajgtTnpRYjNFQlRIVWJpZldiOWRPTTlkNzFUUjBGSVJPamZZZk5mVEZ0V0c0eWJTRmdyWWZ1V0FuVDAxV3hOVnhxMktIYTl3QmhMYUxCWVJqS3dCQUNESzlBVWtUellTN2JEbm9oMWtqYWdUQnc2dDJsanBmaEEwVTZwVkExLUQzbXVlSzljWG9iT2VubWU4cDUyS1VWMzlxLXlyc09wU2VrZS1tSHhLUEtGMEp3bmtseXhmRlVEd0hqdDBHZnJNV0R4OWxxQ2FGb21HOVYxNXg2RVV2c1plMEFsVlhvajU2eGxvT0Z1a0RaRUZhcl9VVk1sd3BmN2MtZmUtV3hlMEFlOEJKaENn?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A key U.S. CRISPR patent fight swings again toward Editas partner Broad", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOcHltUW8weV82akpQdU41MWs2RjhZQmJqRG1uLW4ydmcxemg4OHRHWUNhc0VTa2pWVzVoUGtsY3lVTVA5NlFHakxYWWVHdWNCbW81WTA1OWZYOV9qLU9XcWlETEJPZ21tRVZ5SE10b2RJRTBZS2lxNE1PaG9BOFFVLUo4NTZlZWM1S1F1Z1ZqcFB5cmcwbjdlRWJZMlppWE1rVmFmeTdkR1VQUkdBWXRFS1hGSTFTMEI2dGtXaDlwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline Challenges - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNeWdrN0gzeE5CbWhhNUJZWVc4THZvbXF4UjZZWEdUaUg1aXdBOGZJSEVlcEE0Qy0tWFFDcDVyQlVLMFhpaE90eWJIMzVSOFBhS1FHUUVPbEdLUFl3VW9OQm9MSFpVSDhDbGVkSk1SU05Eak40ZmNfQXBhckJQY0Iyd2RNS3BtaVFDZmpKMUJtT0xQb3dBVmNMMHhBUzRFQlkyWXlScEMzNXFYbFYwS254emlxVDhiVDN1T2c?oc=5", "source_name": "IndexBox", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 111, "total_relevant": 64, "sentiment_summary": {"positive": 5, "negative": 9, "neutral": 50, "score": 50, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 21.8, "count": 39}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 3.26, "latest_week": "2026-07-10", "one_week_move": -10.7, "four_week_move": 30.4, "twelve_week_move": -6.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.308207, "market_dynamics_buy_signal": false, "relative_strength": 4.304693, "fair_value_gap": -23.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.1007, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, +30.4% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 5}, {"label": "www.marketscreener.com", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 39}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-10.7% over one week, +30.4% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Editas Medicine stock holds the line as pipeline work continues."}], "updated_at": "2026-07-16T13:32:13.951734+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}